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The role of conditioning intensity on occurrence of
thrombotic microangiopathy (TMA) after allogeneic
hematopoietic cell transplantation (HCT) has remained
unclear thus far. Here, we retrospectively compared the
incidence of TMA in patients given allogeneic hemato-
poietic stem cells after either nonmyeloablative (n¼ 176)
or high-dose (n¼ 111) conditioning. The 1-year cumula-
tive incidence of TMA was 13% in nonmyeloablative
recipients versus 15% in high-dose conditioning reci-
pients (P¼ 0.5). In multivariate Cox analysis, occurrence
of grade 3–4 acute graft-versus-host disease (GVHD)
(hazard ratio (HR)¼ 2.3, Po0.001), older age (HR¼ 1.01,
P¼ 0.045), and unrelated donors (HR¼ 1.6, P¼ 0.01) were
each associated with a higher risk of TMA, whereas non-
myeloablative conditioning was associated with a lower
risk of TMA (HR¼ 0.6, P¼ 0.01). We conclude that
acute GVHD, age, donor type, and conditioning intensity
might have a role in the physiopathology of TMA after
allogeneic HCT.
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Introduction
Post-transplant thrombotic microangiopathy (TMA) is an
important complication of allogeneic hematopoietic cell
transplantation (HCT).1 This syndrome associates micro-
angiopathic hemolysis with renal and/or neurologic im-
pairment. It has been proposed that endothelial injury
might contribute to the occurrence of TMA after allogeneic
HCT.1 The main mechanisms involved in endothelial injury
after allogeneic HCT include high-dose chemotherapy,
high-dose radiotherapy, and acute graft-versus-host disease
(GVHD). Other factors that have been associated with
TMA after allogeneic HCT include viral or fungal
infections, unrelated donor, ABO incompatibility, and
postgrafting immunosuppression with sirolimus combined
with a calcineurin inhibitor.1,2
The recent development of nonmyeloablative condition-
ing regimens has permitted performing allogeneic trans-
plantation in older patients, those with medical
comorbidities, and those who had failed a high-dose
transplant.3–6 This approach relies nearly exclusively on
the destruction of malignant cells by donor T cells and NK
cells through graft-versus-tumor effects.7,8
In this study, we retrospectively assessed the role of
conditioning intensity on TMA occurrence after allo-
geneic HCT.
Patients and methods
Patients, conditioning regimen, and postgrafting
immunosuppression
Data from 287 patients given allogeneic bone marrow or
peripheral blood stem cells after myeloablative or non-
myeloablative conditioning from January 2000 to July 2008
were retrospectively analyzed. Their characteristics are
listed in Table 1. Although there is no consensus on what
constitutes nonmyeloablative conditioning versus not,9 we
deﬁned nonmyeloablative conditioning in this study as
conditioning that could be performed entirely in the
outpatient setting in most patients. High-dose conditioning
regimens were based on high-dose (single dose of 8Gy or
6 2Gy) total body irradiation (TBI) (n¼ 91), intermedi-
ate (8mg/kg, n¼ 4) or high-dose (16mg/kg, n¼ 8) busul-
fan, or high doses of other alkylating agents (n¼ 8).
Nonmyeloablative conditioning regimens consisted of
2Gy TBI alone (n¼ 3), ﬂudarabine 90mg/m2 plus 2Gy
TBI (n¼ 113), ﬂudarabine 90mg/m2 plus 2 2Gy TBI
(n¼ 17), or ﬂudarabine 90mg/m2 plus cyclophosphamide
3 g/m2 (n¼ 15). In the high-dose group, postgrafting
immunosuppression consisted in cyclosporine alone for 56
patients receiving CD34- or CD133-selected grafts. For the
remaining 55 patients receiving unmanipulated grafts,
postgrafting immunosuppression included tacrolimus plus
mycophenolate mofetil (n¼ 4), cyclosporine alone (n¼ 10),
or cyclosporine plus short methotrexate (n¼ 41, including 7
receiving additional anti-thymocyte globulin). In the
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nonmyeloablative setting, postgrafting immunosuppression
included mycophenolate mofetil combined with cyclospor-
ine or tacrolimus in all patients. Fifty patients undergoing
nonmyeloablative conditioning received CD8-depleted
PBSC,10 119 unmanipulated PBSC, and 7 CD34-selected
PBSC followed by CD8-depleted donor lymphocyte infu-
sions.11
TMA deﬁnition
The following criteria12 were used to deﬁne TMA: (1) RBC
fragmentation andX2 schistocytes per high-power ﬁeld on
peripheral smear; (2) serum LDH increased above institu-
tional baseline; and (3) concurrent renal (doubling of serum
creatinine from baseline or 50% decrease in creatinine
clearance from baseline) and/or neurologic dysfunction
without other explanations. Diagnostic of TMA was
carried out as follows: each patient with (1) evidence of
schistocytes on peripheral smear; (2) serum LDH increased
above institutional baseline; and (3) no apparent alternative
etiologies were prospectively encoded in our clinical
transplant database by YB or FB. EW reviewed all
suspected cases of TMA and excluded cases that did not
fulﬁll the above deﬁnition.
Statistical analyses
The cumulative incidence of TMA in all patients as well as
in patients given high-dose or nonmyeloablative condition-
ing was calculated as described elsewhere.13 Potential
associations between HCT variables and TMA were
assessed using the w2 tests or the Fisher’s exact test
whenever appropriate. A number of factors potentially
associated with the occurrence of TMA were also assessed
in a Cox model: grade 3–4 acute GVHD, donor type
(related versus unrelated), patient age (modeled as a
continuous linear variable), earlier HCT or not, tacrolimus
or cyclosporine as GVHD prophylaxis, HLA compatibility
(6/6 HLA-antigen matched versus other), major ABO
mismatch, minor ABO mismatch, prior administration of
sirolimus (given only as treatment for steroid-refractory
acute or chronic GVHD in our patients), and conditioning
regimen intensity. Statistical analyses were carried out with
Graphpad Prism (Graphpad Software, San Diego, CA,
USA) or with SAS version 9.1 (SAS Institute, Cary, NC,
USA). The threshold signiﬁcance level was 0.05.







Median age 42 (4–66) 57 (10–72)
Gender: male/female 67/44 117/59
Diagnostic; no. of patients (%)
AML 48 (43.2) 25 (14.2)
ALL 11 (9.9) 1 (0.6)
CML 7 (6.3) 5 (2.8)
CLL 3 (2.7) 16 (9.1)
Lymphoma 17 (15.3) 46 (26.1)
MDS et MPD 13 (11.7) 39 (22.2)
MM 4 (3.6) 35 (19.9)
Non-malignant 8 (7.2) 0 (0)
RCC 0 (0) 9 (5.1)
Donor; no. of patients (%)
HLA-identical sibling 58 (52.3) 56 (31.8)
Unrelated 6/6 identical 42 (37.8) 109 (61.9)
X1/6 HLA-mismatched
donors
11 (9.9) 11 (6.3)
Prior transplantation;
no. of patients (%)
10 (9) 97 (55.1)
Conditioning regimen; no. of patients (%)
High-dose TBI-based regimen 91 (82) 0 (0)
Busulfan-based regimen 12 (10.8) 0 (0)
Miscellaneous 8 (7.2) 0 (0)
TBI 2Gy 0 (0) 31 (17.6)
Fludarabine 90mg/m2+
TBI 2Gy
0 (0) 113 (64.2)
Fludarabine 90mg/m2+
TBI 4Gy
0 (0) 17 (9.7)
Fludarabine 90mg/m2+
cyclophosphamide
0 (0) 15 (8.5)
Immunosuppressive regimen; no. of patients (%)
CD34/CD133 selection+CSP 56 (50.5) 7 (+ MMF)11
CSP alone 10 (9) 0 (0)
CSP+MTX 34 (30.6) 0 (0)
CSP+MTX+ATG 7 (6.3) 0 (0)
MMF+CSP/tacrolimus 4 (3.6) 169 (96)
Graft source: bone marrow/PBSC;





ABO Compatibility; no. of patients (%)
Identical 64 (57.7) 103 (58.5)
Major mismatch 26 (23.4) 47 (26.7)
Minor mismatch 27 (24.3) 35 (19.9)
Acute GVHD; no. of patients (%)
Grade 0–1 82 (73.9) 106 (60.2)
Grade 2 14 (12.6) 44 (25)
Grade 3–4 15 (13.5) 26 (14.8)
TMA; no. of patients (%) 17 (15.3) 25 (14.2)
Median time of onset (days) 54 (0–256) 49 (18–519)
Median duration (days) 44 (4–120) 45 (5–246)
Neurologic signs; no. of
patients (%)
12 (10.8) 14 (8)
Treatment; no. of patients (%)
Stop calcineurin inhibitor 2 (1.8) 2 (1.1)
Shift calcineurin inhibitor 8 (7.2) 19 (10.8)
Plasma exchange 10 (9) 15 (8.5)
Rituximab 2 (1.8) 2 (1.1)








TMA as primary cause
of death; no. of patients (%)
1 (0.9) 2 (1.1)
TMA as secondary cause
of death; no. of patients (%)
4 (3.6) 6 (3.4)
Abbreviations: ATG¼ anti-thymocyte globulin; CSP¼ cyclosporine;
MDS¼myelodysplastic syndrome; MMF¼mycophenolate mofetil;
MM¼multiple myeloma; MPD¼myeloproliferative disorder; RCC¼ renal
cell carcinoma; TMA¼ thrombotic microangiopathy.
TMA after HCT





The 1-year cumulative incidence of TMA was 13% in the
nonmyeloablative setting versus 15% in the high-dose
setting (P¼ 0. 5). Median time after transplant for TMA
diagnosis was 52 (range 0–519) days in all patients, 54
(range 0–256) days in the high-dose setting, and 49 (range
18–519) days in the nonmyeloablative setting. Mean
(±s.d.) % of schizocytes was 2.7±1.0 in nonmyeloablative
recipients versus 2.7±1.1 in high-dose recipients (P¼ 0.9).
Twelve percent of nonmyeloablative patients versus 59% of
high-dose recipients were platelet transfusion-dependent at
diagnosis of TMA (P¼ 0.002), whereas 68% of nonmye-
loablative patients versus 88% of high-dose recipients were/
became platelet transfusion-dependent after TMA (P¼ 0.2).
Mean platelet levels at diagnosis of TMA in patients not
requiring platelet transfusion were 58±36 109/l in non-
myeloablative patients versus 57±56 109/l in high-dose
recipients (P¼ 0.9). Mean creatinine levels were 18±10mg/l
in nonmyeloablative patients versus 17±11mg/l in high-dose
recipients (P¼ 0.8).
Risk factors
The clinical factors predicting for TMA in univariate
analyses are listed in Table 2. In multivariate Cox analyses
(Table 3), occurrence of grade 3–4 acute GVHD (hazard
ratio (HR)¼ 2.3, Po0.001), higher patient age (HR¼ 1.01,
P¼ 0.045), and unrelated versus related donors (HR¼ 1.6,
P¼ 0.01) were each associated with a higher risk of TMA,
whereas nonmyeloablative versus high-dose conditioning
was associated with a lower risk of TMA (HR¼ 0.6,
P¼ 0.01). There were no statistically signiﬁcant associa-
tions between TMA and major (HR 0.8, P¼ 0.2) or minor
(HR 1.2, P¼ 0.2) ABO mismatch between recipients and
donors, X1/6 HLA-antigen mismatches or not (HR 1.1,
P¼ 0.8), prior HCT or not (HR¼ 0.8, P¼ 0.3), tacrolimus
or cyclosporine as GVHD prophylaxis (HR 0.7, P¼ 0.2),
or sirolimus administration or not (HR 0.8, P¼ 0.6) .
Median times to achieve 1 109 neutrophils/l and
100 109 platelets/l were 11 and 16 days, respectively, in
patients without TMA versus 11 (P¼ 0.8) and 17 (P¼ 0.7)
days, respectively, in patients who experienced TMA.
Outcomes of TMA
Of the 42 patients who experienced TMA, 30 were treated
by changing immunosuppressive drugs alone (n¼ 12) or in
combination with plasma exchanges (n¼ 18), 7 with plasma
exchanges, 4 with rituximab, and 3 with vincristine.
Twenty-three patients (55%) achieved a resolution of
TMA (deﬁned as schizocytes levels o0.3%, normalization
of LDH levels and decrease in transfusion support) a
median of 48 (range 5–165) days after diagnosis of TMA.
For non-responders (n¼ 19), TMA was deemed the
main cause of death in three patients who had no other
life-threatening complication at that time. Primary causes
of death in the remaining non-responders included infec-
tion (n¼ 4), progressive disease (n¼ 3), bleeding (n¼ 3),
acute GVHD (n¼ 3), chronic GVHD (n¼ 2), and inter-
stitial pneumonia (n¼ 1). Forty-three percent of patients
without TMA versus 69% of those with TMA experienced
secondary platelet failure (P¼ 0.002). One year after TMA,
creatinine (12.8±6.7mg/l versus 12.9±4.3mg/l, P¼ 0.9)
and platelet (195±91 109/l versus 168±96 109/l,
P¼ 0.4) levels were similar in patients without or with
antecedent TMA. One-year survival from diagnosis of
TMA was 20%. By comparison, the 1-year survival from
Table 2 Clinical factors for prediction of TMA








Male 184 24 (13)









HLA-mismatched 22 4 (18) 0.0121
Conditioning regimen
Nonmyeloablative 176 25 (14)
High dose 111 17 (15) 0.8642
Immunosuppression
CD34/CD133+CSP 56 6 (11)
CSP 10 0 (0)
CSP+MTX 35 9 (26)
CSP+MTX+ATG 7 0 (0)
MMF+CSP/Tacro 179 27 (15) 0.1322
Acute GVHD
Grade 0–1 188 20 (11)
Grade 2 58 5 (9)
Grade 3–4 41 17 (41) o0.0001
CMV infection
No 156 20 (13)
Yes 131 22 (17) 0.4027
CMV disease
No 252 33 (13)
Yes 35 9 (25) 0.0698
Invasive aspergillosis
No 250 36 (14)
Yes 37 6 (16) 0.8032
Prior HCT
No 180 26 (14%)
Yes 107 16 (15%) 1.0
Tacrolimus as GVHD prophylaxis
No 200 31 (15.5)
Yes 87 11 (12.6) 0.59
Sirolimus administration
No 277 40 (14)
Yes 10 2 (20) 0.6442
Abbreviations: ATG¼ anti-thymocyte globulin; CSP¼ cyclosporine;
HCT¼hematopoietic cell transplantation; MMF¼mycophenolate mofetil;
Tacro¼ tacrolimus; TMA¼ thrombotic microangiopathy; URD¼ unrelated
donor.
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day 52 in patients who did not experience TMA and were
alive on day 52 (pseudo-landmark analysis7) was 67%
(Po0.0001, Figure 1). As expected, median survival from
TMA diagnosis was higher in patients who achieved
resolution of TMA compared with those who did not
(median 218 days versus 27 days, Po0.001). Further,
1-year survival was signiﬁcantly worse in patients requiring
platelet transfusions after TMA (9%) versus in those who
did not (56%, P¼ 0.006). Finally, 100-day and 1-year
overall survivals from diagnosis of TMA were 40 and 18%,
respectively, in nonmyeloablative recipients versus 41 and
24%, respectively, in high-dose recipients (P¼ 0.8).
Discussion
TMA is a well-known complication of allogeneic HCT.1,2
The relative roles of the conditioning regimen and
alloreactivity in post-transplant TMA have not been
completely elucidated. The primary objective of the current
retrospective study was to compare TMA incidence in
patients given nonmyeloablative versus high-dose condi-
tioning. Other objectives included determining factors
predicting for TMA, and analyzing the impact of TMA
occurrence on OS. Several observations have been made.
First, the incidence of TMA was lower in the non-
myeloablative than in the high-dose setting in the multi-
variate Cox analysis, suggesting that conditioning intensity
might have a role in the physiopathology of post-transplant
TMA. Two recent studies compared the incidence of TMA
after myeloablative or after ‘reduced-intensity’ condition-
ing and failed to show signiﬁcant differences.14,15 This
might be due to the fact that the ‘reduced-intensity’
conditioning regimen (combining relatively high doses of
ﬂudarabine and busulfan 8mg/kg) used in these studies was
still relatively intense and capable of inducing endothelial
damage. In support to this hypothesis, sinusoidal obstruc-
tive syndrome has been observed with this conditioning
regimen, when never in our patients undergoing nonmye-
loablative conditioning. For these reasons, we chose to
classify the four patients given grafts after ﬂudarabine and
busulfan 8mg/kg in this study within the ‘high-dose’
chemotherapy group.
Second, our study showed that severe acute GVHD and
unrelated donor were two strong predictors of TMA
occurrence, in agreement with several earlier reports.15–20
The association between acute GVHD and TMA was not
surprising given that endothelial cells are the targets of
graft-versus-host reactions.21 The association between
unrelated donor and TMA might be explained by the
wider antigenic disparity between donors and recipients in
the setting of unrelated donor transplantation, increasing
the risk of host endothelial injury by donor immune cells.
In contrast, our study failed to show signiﬁcant associ-
ations between infections and post-transplant TMA as
observed in some earlier reports.17,18 The lack of associ-
ation between infection and TMA in this study might be
due to the relatively low number of patients included.
Third, patients who experienced TMA had a dramati-
cally lower probability of survival than those who did not
experience this complication. TMA was the primary cause
of death of 7% of patients with TMA, and a secondary
cause of death in 24%. The poor outcome in patients with
TMA could also be related to the strong associations
observed between TMA and severe GVHD, which is one of
the leading causes of nonrelapse mortality after allogeneic
HCT.4,5,7 Supporting this hypothesis, 26% of patients with
non-responding TMA died of GVHD in this study.
We should acknowledge that comparisons of TMA
incidence between different groups of investigators might
be difﬁcult because of the relatively non-speciﬁc criteria for
diagnosis of TMA and variable sensitivity to the diagnosis
in different institutions. This probably explains the large
range of TMA occurrence reported in different studies
(from 0.5 to 63%).22 However, the incidence of TMA
observed in our high-dose chemotherapy cohort (15% at
1-year) is well in the range of what has been reported
recently by other groups of investigators (10–20%),14,15,23
one of them using a similar deﬁnition for TMA (18%).15
In summary, our data suggest that though severe acute
GVHD and unrelated donor are strong predictors for
TMA occurrence, patients undergoing nonmyeloablative
conditioning might have a slightly lower risk of TMA than
those given high-dose conditioning.









Major ABO mismatch 0.76 (0.52–1.11) 0.15
Minor ABO mismatch 1.2 (0.9–1.8) 0.25
Unrelated donor 1.6 (1.1–2.2) 0.014
1/6 HLA-antigen mismatch 1.1 (0.6–2.0) 0.78
Patient agea 1.01 (1.00–1.03) 0.045
Prior HCT 0.82 (0.56–1.2) 0.33
Tacrolimus or cyclosporine as GVHD
prophylaxis
0.73 (0.47–1.1) 0.16
Sirolimus administration 0.8 (0.36–1.8) 0.59
Abbreviations: HCT¼hematopoietic cell transplantation; TMA¼ throm-
botic microangiopathy.
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Figure 1 Semi-landmark plots illustrating impact of TMA on overall
survival.
TMA after HCT
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